[Breast-like Cancer of Unknown Primary : Implications for Radiological Diagnostics]

Overview

Journal Radiologie (Heidelb)

Specialty Radiology

Date 2023 Mar 28

PMID 36976360

Authors

Andreas Schneeweiss

Lars Buschhorn

Affiliations

Soon will be listed here.

Abstract

Background: Cancer of unknown primary (CUP) is defined by the presence of metastatic disease with an undetectable primary tumor at the time of presentation despite standard-of-care imaging. Although the prognosis of most CUP patients is poor, certain subgroups with more favorable prognosis have been defined.

Diagnostics: Women with isolated axillary lymph node metastases and confirmed histologic adenocarcinoma or poorly differentiated subtype, no other distant metastases, and no evidence of a primary cancer including primary breast carcinoma evaluated by clinical examination, computed tomography of thorax and abdomen, mammography, breast ultrasound, and breast magnetic resonance imaging (MRI) represent a potentially curable subgroup of patients with CUP. Breast MRI is the most important radiological modality in the diagnostic workup of breast-like CUP to exclude a primary cancer in the breast.

Therapy: Breast-like CUP patients are treated according to guidelines for patients with node-positive breast cancer. Standard-of-care adjuvant systemic therapy should be given. Axillary lymph node dissection (ALND) is indicated. If no primary cancer in the breast is detected, surgery of the ipsilateral breast should not be performed. Radiotherapy of the ipsilateral breast and supra-/infraclavicular lymph nodes should be discussed.

References

Pentheroudakis G, Lazaridis G, Pavlidis N . Axillary nodal metastases from carcinoma of unknown primary (CUPAx): a systematic review of published evidence. Breast Cancer Res Treat. 2009; 119(1):1-11. DOI: 10.1007/s10549-009-0554-3. View

Merson M, Andreola S, Galimberti V, Bufalino R, Marchini S, Veronesi U . Breast carcinoma presenting as axillary metastases without evidence of a primary tumor. Cancer. 1992; 70(2):504-8. DOI: 10.1002/1097-0142(19920715)70:2<504::aid-cncr2820700221>3.0.co;2-t. View

Blanchard D, Farley D . Retrospective study of women presenting with axillary metastases from occult breast carcinoma. World J Surg. 2004; 28(6):535-9. DOI: 10.1007/s00268-004-7290-y. View

Hainsworth J, Greco F . Gene expression profiling in patients with carcinoma of unknown primary site: from translational research to standard of care. Virchows Arch. 2014; 464(4):393-402. DOI: 10.1007/s00428-014-1545-2. View

Moran S, Martinez-Cardus A, Sayols S, Musulen E, Balana C, Estival-Gonzalez A . Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis. Lancet Oncol. 2016; 17(10):1386-1395. DOI: 10.1016/S1470-2045(16)30297-2. View

Sasaki E, Tsunoda N, Hatanaka Y, Mori N, Iwata H, Yatabe Y . Breast-specific expression of MGB1/mammaglobin: an examination of 480 tumors from various organs and clinicopathological analysis of MGB1-positive breast cancers. Mod Pathol. 2006; 20(2):208-14. DOI: 10.1038/modpathol.3800731. View

Leibman A, Kossoff M . Mammography in women with axillary lymphadenopathy and normal breasts on physical examination: value in detecting occult breast carcinoma. AJR Am J Roentgenol. 1992; 159(3):493-5. DOI: 10.2214/ajr.159.3.1503012. View

Kolb T, LICHY J, Newhouse J . Occult cancer in women with dense breasts: detection with screening US--diagnostic yield and tumor characteristics. Radiology. 1998; 207(1):191-9. DOI: 10.1148/radiology.207.1.9530316. View

Costantini M, Montella R, Fadda M, Garganese G, Di Leone A, Sanchez A . Axillary Nodal Metastases from Carcinoma of Unknown Primary (CUPAx): Role of Contrast-Enhanced Spectral Mammography (CESM) in Detecting Occult Breast Cancer. J Pers Med. 2021; 11(6). PMC: 8225076. DOI: 10.3390/jpm11060465. View

10.

Chen C, Orel S, Harris E, Schnall M, Czerniecki B, Solin L . Outcome after treatment of patients with mammographically occult, magnetic resonance imaging-detected breast cancer presenting with axillary lymphadenopathy. Clin Breast Cancer. 2004; 5(1):72-7. DOI: 10.3816/cbc.2004.n.012. View

11.

Obdeijn I, Tilanus-Linthorst M, Wiggers T, Oudkerk M . MR imaging-guided sonography followed by fine-needle aspiration cytology in occult carcinoma of the breast. AJR Am J Roentgenol. 2000; 174(4):1079-84. DOI: 10.2214/ajr.174.4.1741079. View

12.

Buchanan C, Morris E, Dorn P, Borgen P, Van Zee K . Utility of breast magnetic resonance imaging in patients with occult primary breast cancer. Ann Surg Oncol. 2005; 12(12):1045-53. DOI: 10.1245/ASO.2005.03.520. View

13.

Schorn C, Fischer U, Luftner-Nagel S, Westerhof J, Grabbe E . MRI of the breast in patients with metastatic disease of unknown primary. Eur Radiol. 1999; 9(3):470-3. DOI: 10.1007/s003300050694. View

14.

Harms S, Westbrook K, Korourian S, Klimberg V . Role of breast magnetic resonance imaging in determining breast as a source of unknown metastatic lymphadenopathy. Am J Surg. 2000; 178(6):496-500. DOI: 10.1016/s0002-9610(99)00221-4. View

15.

Morris E, Schwartz L, Dershaw D, Van Zee K, Abramson A, Liberman L . MR imaging of the breast in patients with occult primary breast carcinoma. Radiology. 1997; 205(2):437-40. DOI: 10.1148/radiology.205.2.9356625. View

16.

Olson Jr J, Morris E, Van Zee K, Linehan D, Borgen P . Magnetic resonance imaging facilitates breast conservation for occult breast cancer. Ann Surg Oncol. 2000; 7(6):411-5. DOI: 10.1007/s10434-000-0411-4. View

17.

de Bresser J, de Vos B, van der Ent F, Hulsewe K . Breast MRI in clinically and mammographically occult breast cancer presenting with an axillary metastasis: a systematic review. Eur J Surg Oncol. 2009; 36(2):114-9. DOI: 10.1016/j.ejso.2009.09.007. View

18.

Bedrosian I, Schlencker J, Spitz F, Orel S, Fraker D, Callans L . Magnetic resonance imaging-guided biopsy of mammographically and clinically occult breast lesions. Ann Surg Oncol. 2002; 9(5):457-61. DOI: 10.1007/BF02557268. View

19.

Floery D, Helbich T . MRI-Guided percutaneous biopsy of breast lesions: materials, techniques, success rates, and management in patients with suspected radiologic-pathologic mismatch. Magn Reson Imaging Clin N Am. 2006; 14(3):411-25, viii. DOI: 10.1016/j.mric.2006.10.002. View

20.

Kuhl C, Morakkabati N, Leutner C, Schmiedel A, Wardelmann E, Schild H . MR imaging--guided large-core (14-gauge) needle biopsy of small lesions visible at breast MR imaging alone. Radiology. 2001; 220(1):31-9. DOI: 10.1148/radiology.220.1.r01jl0731. View